Peptide Therapies in Thyroid Health: Emerging Applications in Endocrine and Immune Modulation

Thyroid disorders, particularly autoimmune conditions such as Hashimoto's thyroiditis, are frequently associated with persistent systemic symptoms despite biochemical normalization with standard hormone replacement, prompting investigation into adjunctive strategies that target immune, metabolic, and neuroendocrine contributors to thyroid dysfunction. Peptide-based therapeutics are an emerging area of research in regenerative and endocrine medicine, with experimental studies demonstrating effects on immune signaling, inflammatory regulation, tissue repair, and cellular stress responses. This review examines the mechanistic rationale for peptide interventions relevant to thyroid biology and summarizes the current state of evidence for selected peptides, including thymosin alpha-1, thymosin beta-4, BPC-157, and growth hormone secretagogues. Available data consist primarily of preclinical investigations, mechanistic studies, and early exploratory clinical reports rather than large, randomized trials focused on thyroid-specific outcomes. Safety profiles vary across peptide classes, and clinical use remains largely investigational in the context of thyroid disease. This review presents potential biologic pathways linking peptide activity to immune and metabolic aspects of thyroid disorders, as well as regulatory and ethical considerations surrounding emerging peptide applications. Substantial evidence gaps persist, and well-designed thyroid-focused clinical trials are needed to clarify safety, efficacy, and appropriate clinical roles. Peptide therapeutics, therefore, represent a developing research domain whose relevance to thyroid care remains to be established through rigorous investigation.